FDG PET衍生参数作为进展期恶性胸膜间皮瘤治疗患者的预后工具
该回顾性研究纳入55例2006年3月至2015年2月间接受FDG PET/CT引导下挽救性螺旋断层放疗的恶性胸膜间皮瘤患者,评估FDG PET衍生参数对总生存、局部无复发生存和远处无复发生存的预测价值。结果显示BTV及TLG40/50/60是总生存的最显著预测因子,TLG40/50/60与局部无复发生存显著相关,FDG PET衍生参数可有效区分预后不良患者。
要点
- BTV和TLG40、TLG50、TLG60是总生存的最显著预测因子(p < 0.005)。
- MTV60 >5 cm3且TLG40 >334.4的患者中位总生存为4.8个月,低于较小值患者的13.8个月和16.1个月。
- TLG40、TLG50、TLG60与局部无复发生存显著相关(p < 0.015)。
核心结论
- FDG PET衍生参数可有效区分预后不良的恶性胸膜间皮瘤患者,并可能有助于筛选适合挽救性螺旋断层放疗的患者。
研究设计与样本
- 回顾性评估纳入55例恶性胸膜间皮瘤患者,患者于2006年3月至2015年2月间在接受既往手术联合化疗后接受FDG PET/CT引导的挽救性螺旋断层放疗。
- 采用单因素Cox回归分析评估BTV、SUVmean、SUVmax、MTV和TLG(分别以40%、50%和60%摄取阈值测量)对总生存、局部无复发生存和远处无复发生存的影响,随后采用逻辑回归识别筛选生存较差患者的最佳FDG PET衍生参数。
主要发现
- 螺旋断层放疗结束后中位总生存为9.1个月(范围0.0 - 69.6个月),末次随访时54/55例患者死亡。
- MTV60 >5 cm3且TLG40 >334.4的患者中位总生存为4.8个月,而相应值较小的患者中位总生存分别为13.8个月和16.1个月。
- 中位局部无复发生存为6.2个月(范围1.2 - 39.4个月),中位远处无复发生存为6.5个月(范围0.0 - 66.4个月)。
- MTV40 >39.6 cm3的患者中位远处无复发生存为6.4个月,TLG40 >334.4的患者为6.2个月,而相应值较小的患者分别为17个月和18.8个月。
- BTV、TLG40和MTV40在总生存/局部无复发生存/远处无复发生存较差(中位生存时间低于中位值)的患者中也被发现是良好的预测因子。
关键数值与推荐
- BTV和TLG40、TLG50、TLG60是总生存的最显著预测因子(p < 0.005)。
- TLG40、TLG50、TLG60与局部无复发生存显著相关(p < 0.015)。
- MTV60 >5 cm3且TLG40 >334.4的患者中位总生存为4.8个月,低于相应值较小患者的13.8个月和16.1个月。
- MTV40 >39.6 cm3的患者中位远处无复发生存为6.4个月,TLG40 >334.4的患者为6.2个月,低于相应值较小患者的17个月和18.8个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The value of FDG PET-derived parameters in predicting overall survival (OS), local relapse-free survival (LRFS) and distant relapse-free survival (DRFS) in treated patients with malignant pleural mesothelioma (MPM) was evaluated. METHODS: This retrospective evaluation included 55 MPM patients treated between March 2006 and February 2015 with FDG PET/CT-guided salvage helical tomotherapy (HTT) after previous surgery plus chemotherapy. Univariate Cox regression analysis was performed to assess the impact of the following FDG PET-derived parameters: biological target volume (BTV), mean and maximum standardized uptake values (SUVmean/max), metabolic tumour volume (MTV) and total lesion glycolysis (TLG), measured using different uptake thresholds (40%, 50% and 60%). Logistic regression was then performed to identify the best FDG PET-derived parameters for selecting patients with poorer survival. RESULTS: The median OS was 9.1 months (range 0.0 - 69.6 months) after the end of HTT; 54/55 patients were dead at the last follow-up. BTV and TLG40, TLG50 and TLG60 were the most significant predictors of OS (p < 0.005). The median OS was 4.8 months in patients with MTV60 >5 cm3 and TLG40 >334.4, compared with 13.8 months and 16.1 months in patients with smaller values, respectively. The median LRFS and DRFS were 6.2 months (range 1.2 - 39.4 months) and 6.5 months (0.0 - 66.4 months), respectively. TLG40, TLG50 and TLG60 were significantly correlated with LRFS (p < 0.015). Median DRFS was 6.4 months in patients with MTV40 >39.6 cm3 and 6.2 months in patients with TLG40 >334.4, compared with 17 months and 18.8 months in patients with smaller values. BTV, TLG40 and MTV40 were also found to be good predictors in patients with poor OS/LRFS/DRFS (median survival times less than the median values). CONCLUSION: FDG PET-derived parameters effectively discriminated patients with a poor prognosis and may be helpful in the selection of MPM patients for salvage HTT.
引用
- Incerti E, Broggi S, Fodor A, et al. FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients. Eur J Nucl Med Mol Imaging. 2018. PMID: 29876617. doi:10.1007/s00259-018-4056-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。